Author(s): Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, et al.
Objective: To determine whether cognitive status in patients with amyotrophic lateral sclerosis (ALS) is a useful predictor of attrition and motor and cognitive decline.
Methods: Cognitive testing was undertaken in a large population-based cohort of incident ALS patients using a longitudinal, case-control study design. Normative data for neuropsychological tests were generated using age-, sex-, and education-matched healthy controls who also underwent repeated assessments. Data were analyzed to generate models for progression/spread.
Results: One hundred eighty-six patients with ALS who had no evidence of C9orf72 hexanucleotide repeat expansion were enrolled. A second and third assessment were undertaken in 98 and 46 of the patients with ALS, respectively. Executive impairment at the initial visit was associated with significantly higher rates of attrition due to disability or death and faster rates of motor functional decline, particularly decline in bulbar function. Decline in cognitive function was faster in patients who were cognitively impaired at baseline. Normal cognition at baseline was associated with tendency to remain cognitively intact, and with slower motor and cognitive progression.
Conclusions: Non-C9orf72–associated ALS is characterized by nonoverlapping cognitive subgroups with different disease trajectories. These findings have important implications for models of ALS pathogenesis, and for future clinical trial design.
Author(s): Lattante S, Conte A, Zollino M, Luigetti M, Del Grande A, et al.
Author(s): Sedda A
Author(s): Strong MJ, Abrahams S, Goldstein LH, Wooley S, Mclaughlin P, et al.
Author(s): Chiò A, Battistini S, Calvo A, Caponnetto C, Conforti FL, et al.
Author(s): Sabatelli M, Marangi G, Conte A, Tasca G, Zollino M, et al.
Author(s): Lattante S, Pomponi MG, Conte A, Marangi G, Bisogni G, et al.
Author(s): McCullagh S, Moore M, Gawel M, Feinstein A
Author(s): Agosta F, Al-Chalabi A, Filippi M, Hairdman O, Kaji R, et al.
Author(s): Murphy J, Ahmed F, Lomen-Hoert C
Author(s): Pagnini F, Zachary S (Ed)
Author(s): Goldstein LH, Abrahams S
Author(s): Robinson KM, Lacey SC, Grugan P, Glosser G, Grossman M, et al.
Author(s): Kim SM, Lee KM, Jong YH, Park KS, Yang JH, et al.
Author(s): Grossman AB, Bonnie EL, Bradley WG
Author(s): Lulè D, Paulì S, Altinas E, Singer U, Mèrk T, et al.
Author(s): Brown WA, Mueller PS
Author(s): Houpt JL, Gould BS, Norris FHJr
Author(s): Peters PK, Swenson WM, Mulder DW
Author(s): Poletti B, Carelli L, Lafronza A, Solca F, Faini A, et al.
Author(s): McElhiney MC, Rabkin JC, Gordon PH, Goetz R, Mitsumoto H
Author(s): Talbot K, Ansorge O
Author(s): Girardi A, MacPherson SE, Abrahams S
Author(s): Lillo P, Savage S, Mioshui E, Kiernan MC, Hodges JR
Author(s): Frances A
Author(s): Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, et al.
Author(s): Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, et al.
Author(s): Benaim C, Desnuelle C, Fourniere-Mehouas M
Author(s): ALS CNTF Treatment Study (ACTS) Phase I-II Study Group
Author(s): Cedarbaum JM, Stambler N
Author(s): Poletti B, Solca F, Carelli L, Madotto F, Lafronza A, et al.
Author(s): Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, et al.